Glucose-lowering medicines for type 2 diabetes

被引:0
作者
Davoren, Peter [1 ,2 ]
机构
[1] Gold Coast Univ Hosp, Diabet & Endocrinol, Southport, Qld, Australia
[2] Griffith Univ, Sch Med, Southport, Qld 4215, Australia
关键词
RISK; METFORMIN; THERAPY;
D O I
暂无
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
Background There is an increasing array of medicines available to improve blood glucose control in type 2 diabetes. Finding the best combination for an individual patient requires an assessment of the patient's characteristics and understanding the mechanism of action for each drug. Objective The aim of this article is to provide a rational approach for choosing between the various blood glucose-lowering medicines available for treatment of patients with type 2 diabetes mellitus. Discussion Metformin is the first choice of glucose-lowering medicines for most patients with type 2 diabetes. Sulphonylureas have proven benefits in long-term trials. Insulin is required in patients with symptoms of insulin deficiency. Glucagon-like peptide 1 agonists and sodium-glucose co-transporter 2 inhibitors provide some assistance in weight loss as well as improving blood glucose control. Dipeptidyl peptidase 4 inhibitors provide an alternative to metformin and sulphonylureas, especially when side effects of those drugs limit their use. Re-assessing blood glucose control after an appropriate trial period before deciding on continuing use is appropriate.
引用
收藏
页码:272 / 276
页数:5
相关论文
共 15 条
[1]   Effects of Exenatide Combined with Lifestyle Modification in Patients with Type 2 Diabetes [J].
Apovian, Caroline M. ;
Bergenstal, Richard M. ;
Cuddihy, Robert M. ;
Qu, Yongming ;
Lenox, Sheila ;
Lewis, Michelle S. ;
Glass, Leonard C. .
AMERICAN JOURNAL OF MEDICINE, 2010, 123 (05) :468.e9-468.e17
[2]  
Davoren P., 2014, ANUST PRESCR, V37, P2, DOI [10.18773/austprescr.2014.001, DOI 10.18773/AUSTPRESCR.2014.001]
[3]   Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events):: a randomised controlled trial [J].
Dormandy, JA ;
Charbonnel, B ;
Eckland, DJA ;
Erdmann, E ;
Massi-Benedetti, M ;
Kmoules, IK ;
Skene, AM ;
Tan, MH ;
Lefébvre, PJ ;
Murray, GD ;
Standl, E ;
Wilcox, RG ;
Wlhelmsen, L ;
Betteridge, J ;
Birkeland, K ;
Golay, A ;
Heine, RJ ;
Korányi, L ;
Laakso, M ;
Mokán, M ;
Norkus, A ;
Pirags, V ;
Podar, T ;
Scheen, A ;
Scherbaum, W ;
Schernthaner, G ;
Schmitz, O ;
Skrha, J ;
Smith, U ;
Taton, J .
LANCET, 2005, 366 (9493) :1279-1289
[4]   Contraindications to metformin therapy in patients with Type 2 diabetes - a population-based study of adherence to prescribing guidelines [J].
Emslie-Smith, AM ;
Boyle, DIR ;
Evans, JMM ;
Sullivan, F ;
Morris, AD .
DIABETIC MEDICINE, 2001, 18 (06) :483-488
[5]   A new blood glucose management algorithm for type 2 diabetes [J].
Gunton, Jenny E. ;
Cheung, N. Wah ;
Davis, Timothy M. E. ;
Zoungas, Sophia ;
Colagiuri, Stephen .
MEDICAL JOURNAL OF AUSTRALIA, 2014, 201 (11) :650-653
[6]   Risk of pancreatitis in patients treated with incretin-based therapies [J].
Meier, Juris J. ;
Nauck, Michael A. .
DIABETOLOGIA, 2014, 57 (07) :1320-1324
[7]   Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial [J].
Nauck, Michael A. ;
Del Prato, Stefano ;
Meier, Juris J. ;
Duran-Garcia, Santiago ;
Rohwedder, Katja ;
Elze, Martina ;
Parikh, Shamik J. .
DIABETES CARE, 2011, 34 (09) :2015-2022
[8]   Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes (vol 356, pg 2457, 2007) [J].
Nissen, Steven E. ;
Wolski, Kathy .
NEW ENGLAND JOURNAL OF MEDICINE, 2007, 356 (24) :2457-2471
[9]   Bone Loss and Fracture Risk Associated with Thiazolidinedione Therapy [J].
Riche, Daniel M. ;
King, S. Travis .
PHARMACOTHERAPY, 2010, 30 (07) :716-727
[10]  
Salpeter SR, 2010, COCHRANE DATABASE SY